Modulation of specific IgE’s in patients with atopic dermatitis under the treatment with Lebrikizumab

Modulation of specific IgE’s in patients with atopic dermatitis under the treatment with Lebrikizumab - IGELEBRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036456

Enrollment

Registered

2025-03-24

Start date

2025-02-13

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L20

Interventions

Group 1: Collection of surrogate parameters before initiation and during therapy with an IL-13 antagonist (Lebrikizumab) in patients with atopic eczema - Total- and specific IgE at weeks 0, 26, and 52

Eligibility

Sex/Gender

All

Age

12 Years to 88 Years

Inclusion criteria

Inclusion criteria: - Patient with moderate or severe atopic dermatitis with indication for systemic therapy - Proven sensitation to relevant allergenes - Informed consent of the patient for study inclusion

Exclusion criteria

Exclusion criteria: - Ongoing immunosuppression - Systemic pretreatments for atopic eczema - Previous desensitization (immunotherapy) to relevant allergens

Design outcomes

Primary

Measure	Time frame
- Drop of specific and total IgE levels after 52 weeks of treatment with Lebrikizumab compared to before treatment	—

Secondary

Measure	Time frame
- Comparison of prick test results using allergens from individual sensitizations before treatment start and after 52 weeks - Comparison of basophil activation tests using allergens from individual sensitizations before treatment start and after 52 weeks	—

Countries

Germany

Contacts

Public ContactJoshua Aulenbacher

Dermatologie am Biederstein, Kinikum Rechts der Isar

joshua.aulenbacher@mri.tum.de089 4140 8499

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026